The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%.

The approval was based on results from the FINEARTS-HF trial, presented at ESC Congress 2024 and published in the New England Journal of Medicine, which observed a 16% relative risk reduction of the composite primary endpoint of cardiovascular death, hospitalization for HF or an urgent HF visit in patients treated with finerenone vs. placebo.

For more information, access the Bayer press release.

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: ACC Advocacy, United States Food and Drug Administration, Heart Failure